Last reviewed · How we verify

NCT07177144

Does Vnotes Salpingectomy Reduce Ovarian Reserve?

Completed NA Last updated 19 November 2025
What this trial tests

NA trial testing anti müllerian hormone in Vnotes in 46 participants. Completed in 17 November 2025.

Timeline
19 June 2025
Primary endpoint
17 November 2025
17 November 2025

Quick facts

Lead sponsorGaziosmanpasa Research and Education Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposediagnostic
Enrollment46
Start date19 June 2025
Primary completion17 November 2025
Estimated completion17 November 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Gaziosmanpasa Research and Education Hospital

Who can join

Adults 18 to 45, female only, with Vnotes or Salpingectomy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparison of Transvaginal Natural Orifice Transluminal Endoscopic Surgery and Conventional Laparoscopy in terms of their effects on ovarian reserve in Opportunistic Bilateral Salpingectomy for Permanent Female Sterilization

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. When Performing vNOTES Salpingectomy, Are We Damaging the Ovarian Reserve? Results From a Randomized, Controlled Trial.
    Yıldız E, Coşkun ES, Timur GY, Bacak HB, et al · · 2026 · cited 1× · PMID 41662907 · DOI 10.1016/j.jmig.2026.02.009

Verify or expand the search:

Other Gaziosmanpasa Research and Education Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07177144.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing